Background
==========

Esophageal carcinoma (ESCA) is the eighth most common cancer and the sixth most common cancer leading to death, with more than 456 000 sufferers worldwide \[[@b1-medscimonit-26-e923934],[@b2-medscimonit-26-e923934]\]. Previous studies have documented that the overall 5-year survival of ESCA patients is approximately 15% to 25% \[[@b2-medscimonit-26-e923934]\].

ESCA includes two major subtypes: esophageal squamous cell carcinoma (ESCC), the predominant form, and esophageal adenocarcinoma (EAC), which affects a growing percentile of patients \[[@b3-medscimonit-26-e923934]\]. There are distinct differences between the pathological risks underlying these histological subtypes that affect their incidence. The mechanism underlying ESCC is complicated and embraces a broad spectrum of hazards contributing to its rapidly increasing incidence. There are two primary types of risk factors: inheritable and environmental factors. There are several environmental risks, including alcohol and tobacco consumption, low vegetable and fruit intake, and low socioeconomic status \[[@b4-medscimonit-26-e923934]\]. As for EAC, almost all cases are complicated by precancerous lesions called Barrett's oesophagus, which mainly derive from gastroesophageal reflux disease, a common condition throughout the human population \[[@b5-medscimonit-26-e923934]\]. Despite this, the risk of progression from this kind of chronic premalignant condition into EAC is low; approximately 0.12%, which makes it difficult to perform predictions of EAC from Barrett's oesophagus. Fortunately, there are some mechanistic connections between heritable elements and EAC. A meta-analysis demonstrated that single nucleotide polymorphisms (SNPs) located in the LPA, TPPP, and CEP72 genes were associated with high risk of both EAC and its premalignant precursor. SNPs near HTR3C and ABCC5 implicated this region as a specific locus for EAC \[[@b6-medscimonit-26-e923934]\].

Given its extremely invasive nature and poor prognosis among gastrointestinal malignancies, a majority of people die from ESCA, placing a heavy burden on the international economy \[[@b7-medscimonit-26-e923934]\]. When it comes to treatment, ESCA demands multidisciplinary knowledge, covering endoscopic procedures, neoadjuvant therapy with chemotherapy, chemoradiotherapy, surgery, and other procedures \[[@b8-medscimonit-26-e923934]\]. If early-stage, mild symptoms are neglected by patients and clinical workers, treatment will be even more difficult. Studies have demonstrated that early diagnosis of dysplasia allows for decisive therapy and ultimately lengthens survival time \[[@b9-medscimonit-26-e923934]\]. In addition, immuno-oncology therapies with molecular targets have emerged, promising early results among ESCA patients \[[@b10-medscimonit-26-e923934]\]. Pursuit of available biomarkers therefore has the potential to exert positive effects via early diagnosis and treatment.

At present, exploring pathological mechanisms of diseases based on bioinformatics theories has becoming an increasingly important and effective method \[[@b11-medscimonit-26-e923934]\]. With bioinformatics analysis, researchers can gain comprehensive knowledge regarding the studied diseases from molecular data. More crucially, it can provide novel insight leading to early diagnosis, definitive treatment, and survival prediction \[[@b12-medscimonit-26-e923934]\]. Previous research in the bioinformatics field has yielded some achievements in ESCA knowledge, such as identification of associated genes and pathways and altered methylation associated with ESCA pathology \[[@b13-medscimonit-26-e923934],[@b14-medscimonit-26-e923934]\]. However, analytical ability for ESCA has been limited due to insufficient sample size and a lack of in-depth evaluation of key genes which play a dominant role in the malignant development of ESCA.

Learning from our predecessors, we added the expression data from two microarrays to our research to enlarge the sample size, in order to reduce errors. We aimed to seek out hub genes and pathways involved in ESCA using integrated analysis of the chosen microarray data. Moreover, we aimed to conduct further expression and survival assessments of hub genes, which may provide reference and direction for early diagnosis and practical therapeutic strategies for ESCA. To our knowledge, the present study represents the first assessment of key hub genes associated with ESCA using bioinformatics methods to obtain information on altered expression of these genes at different stages, as well as their prognostic impact for diagnosed patients.

Material and Methods
====================

Acquisition of datasets
-----------------------

The appropriate datasets were obtained from the Gene Expression Omnibus (GEO) database (*<http://www.ncbi.nlm.nih.gov/geo>*). Inclusion criteria were as follows: (1) sample from human esophageal tissue (cell-line and animal experiments excluded); (2) normalized expression data; (3) coverage of diverse types of ESCA, including ESCC, EAC, and rare types of ESCA; (4) control group from non-carcinoma oesophageal tissue; (5) inclusion of mRNA expression level.

After an overall scrutiny, the datasets of GSE100942 \[[@b15-medscimonit-26-e923934]\] and GSE111044 \[[@b16-medscimonit-26-e923934]\] were selected as they suited the inclusion standards we set up. Moreover, both of them had been created recently, in the past 5 years, which met the need for timeliness. GSE100942 consisted of ten samples, including five samples from ESCC and five samples from normal esophageal tissue. GSE111044 was made up of six samples, including three samples from small cell esophageal carcinoma (SCEC) and three samples from corresponding normal tissue.

Identification of DEGs
----------------------

GEO2R (*<http://www.ncbi.nlm.nih.gov/geo/geo2r/>*), an online web tool affiliated with GEO, already provided access to the data set and collection. Further analysis was applied to the prepared datasets using GEO2R. The selected datasets were divided into two groups: the normal tissue group and the cancer group. Subsequently, direct statistical analysis of each dataset was conducted with cutoff values of: p\<0.01 and 2 \|log FC\| ≥3. The intersection of the two filtered datasets, representing DEGs, was identified by a web-based tool named Venny v2.1. (*<https://bioinfogp.cnb.csic.es/tools/venny/>*).

Enrichment analysis
-------------------

Gene ontology (GO) enrichment analysis was conducted using the online platform Metascape \[[@b17-medscimonit-26-e923934]\] (*<http://metascape.org>*). A set of functional classifications and annotations are included in Metascape, such as biological processes (BP), cellular components (CC), and molecular functions (MF). The norm for statistical significance of p\<0.05 was determined as the threshold value for our statistical analysis, to deeply screen enriched GO terms.

The Kyoto Encyclopedia of Genes and Genomes (KEGG) Orthology Based Annotation System, third version (KOBAS v3.0) \[[@b18-medscimonit-26-e923934]\] (*<http://kobas.cbi.pku.edu.cn/kobas3>*) was used to perform the KEGG pathway enrichment analysis. A corrected p value \<0.05 was considered to represent statistical significance. Moreover, we used the remaining pathways to draw a bubble chart of the top 20 pathways as a visualization, using OmicShare tools (*<https://www.omicshare.com.html>*).

Construction of the PPI network
-------------------------------

The screened DEGs were imported into the Search Tool for the Retrieval of Interacting Genes (STRING) \[[@b19-medscimonit-26-e923934]\] (*<http://string.embl.de/>*) to begin network analysis. STRING possesses a potent ability to process multiple proteins or amino acid sequences input by users, which are then used to construct a protein-protein interaction (PPI) network. Conveniently, STRING can provide various types of exported files, including tsv, PNG, and tables. In our research, we downloaded the requisite files (tsv and PNG) to prepare for validation of hub genes and further research.

Expression analysis of hub genes
--------------------------------

In light of degree level, hub genes were identified by cytohubba, an analytic tool attached to Cytoscape software \[[@b20-medscimonit-26-e923934]\] (*<https://cytoscape.org/>*). Cytohubba can rank nodes in a network by their network features in order to find a requested objective from imported elements of a PPI network, at levels of degree, closeness, and so on.

We successfully used Gene Expression Profiling Interactive Analysis (GEPIA2) \[[@b21-medscimonit-26-e923934]\] (*<http://gepia2.cancer-pku.cn>*) to compare mRNA expression levels between ESCA tissue and paired normal tissue. Additionally, differential expression levels in patients at each stage of ESCA were compared in GEPIA.

Survival analysis of hub genes
------------------------------

OncoLnc \[[@b22-medscimonit-26-e923934]\] (*<http://www.oncolnc.org/>*) was used to analyze predictive hub gene data. OncoLnc is an efficient online analytic box, which can supply survival data correlated with mRNA expression level based on The Cancer Genome Atlas (TCGA) data. We set 50 as the cutoff to divide paired data into high- and low-expression groups, for a Kaplan plot of input genes related to ESCA.

Results
=======

Confirmation of DEGs
--------------------

After GEO2R analysis of the two screened datasets, the criterion p\<0.01 and 2 \|log FC\| ≥3 was utilized for statistical analysis. A total of 3170 and 318 gene fragments were selected from the GSE111044 and GSE100942 datasets. Genes found to be present in both datasets were selected as DEGs. Consequently, a total of 210 DEGs were screened from the two genetic datasets ([Table 1](#t1-medscimonit-26-e923934){ref-type="table"}, [Figure 1](#f1-medscimonit-26-e923934){ref-type="fig"}).

GO enrichment analysis
----------------------

In total, 114 GO terms mediated by the DEGs were identified as enriched, spanning the categories of molecular function (MF), cellular component (CC), and biological process (BP) ([Table 2](#t2-medscimonit-26-e923934){ref-type="table"}). The MF results implicated DEGs that were profoundly enriched in actin binding, extracellular matrix structural constituents, and structural constituents of muscle ([Figure 2](#f2-medscimonit-26-e923934){ref-type="fig"}). The CC results indicated that DEGs were enriched in chromosome, centromere, spindle, extracellular matrix, and stress fibers ([Figure 3](#f3-medscimonit-26-e923934){ref-type="fig"}). With respect to BP, DEGs were noticeably enriched in processes related to cell division, mitotic cell cycle phase transition, muscle system process, and muscle structural development ([Figure 4](#f4-medscimonit-26-e923934){ref-type="fig"}). We then obtained the top 20 terms of the GO functional enrichment analysis ([Figure 5](#f5-medscimonit-26-e923934){ref-type="fig"}). The results indicated that ESCA-related DEGs were mainly involved in cell division, muscle system process, development and attachment of spindle microtubules to the kinetochore at the midbody, and extracellular matrix.

Enrichment analysis of the KEGG pathway
---------------------------------------

In total, 107 pathways connected with DEGs were procured through KOBAS v3.0. The corrected p value \<0.05 was set as the statistical cutoff, and 60 pathways without statistical difference were rejected. The remaining 47 pathways with statistical significance are presented in [Table 3](#t3-medscimonit-26-e923934){ref-type="table"}. Among these remaining pathways, we chose the top 20 enriched pathways using OmicShare tools ([Figure 6](#f6-medscimonit-26-e923934){ref-type="fig"}). These pathways revealed that a broad spectrum of DEGs participated in the cell cycle, pathways in cancer, the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) signaling pathway, the cGMP-protein kinase G (PKG) signaling pathway, cytokine-cytokine receptor interaction, and vascular smooth muscle contraction.

Construction of the PPI network and identification of hub genes
---------------------------------------------------------------

The PPI network exported by STRING comprised 202 nodes and 1571 edges ([Figure 7](#f7-medscimonit-26-e923934){ref-type="fig"}). The modular interaction network was viewed as statistically enriched, due to the enrichment p value \<1.0e-16 (\<0.05). The top 10 genes in the PPI network, in terms of degree ranking, were regarded as hub genes ([Figure 8](#f8-medscimonit-26-e923934){ref-type="fig"}); these genes probably play crucial roles in the incidence and development of ESCA. TOP2A was in the highest rank among all the DEGs, followed by UBE2C, BUB1, KIF20A, TTK, CCNB2, KIF2C, TPX2, CCNA2, and CCNB1.

Expression analysis of hub genes
--------------------------------

The expression boxplots of the hub genes, conveyed on the basis of TCGA and GTEx data, demonstrated that these hub genes were upregulated in ESCA tissue compared with normal esophageal tissue ([Figure 9](#f9-medscimonit-26-e923934){ref-type="fig"}). Further, we evaluated the expression level of the hub genes at different pathological stages among ESCA patients (stage I, stage II, stage III, and stage IV patients). The stage-plots were scored using GEPIA ([Figure 10](#f10-medscimonit-26-e923934){ref-type="fig"}). As is shown below, the expression level of the hub genes differed at different stages.

Survival analysis for the hub genes
-----------------------------------

The survival curve output by OncoLnc showed that all the hub genes with high expression, in comparison with those with low expression, improved the percentage of late survival, after the 2000-day timepoint (\>2000 on the x axis) ([Figure 11](#f11-medscimonit-26-e923934){ref-type="fig"}). Moreover, when the surviving percentile of ESCA patients was stationary, high expression of the hub genes prolonged survival time. However, the hub genes exhibited few associations with early survival.

Discussion
==========

ESCA is a major global health challenge with multifactorial etiology, including both genetic and environmental components. Efforts to detect inchoate changes have attenuated the development of malignant cancer, and have even had some success in prevention \[[@b9-medscimonit-26-e923934]\]. Therefore, it is of vital importance to seek out predictive indicators and therapeutic markers for ESCA.

In our research, 210 DEGs were screened from two genetic expression datasets, via the GEO bioinformatics portal. Then, GO function enrichment analysis and KEGG pathway enrichment analysis were applied to filter the DEGs. A PPI network was constructed using STRING to obtain hub genes that are likely to be central to the ESCA pathological process. Most previous studies in this field stopped at this point, resulting in limited clinical usefulness. Therefore, we implemented further analysis targeting the crucial hub genes identified in the first steps of our study. We focused on the assessment of screened hub genes with greater possibility as new therapeutic targets for treating ESCA. We conducted expression analysis of these hub genes in patients at different stages of ESCA, as well as prognostic analysis. These analyses showed the potential of these hub genes as biomarkers for appraisal in the process of therapy and post-therapy.

The results of GO functional enrichment analysis identified several DEGs exhibiting a distinction from genes expressed in healthy esophageal tissue. The DEGs were principally targeted to the midbody, with functions related to cell division and attachment of spindle microtubules to the kinetochore. The results suggested that multitudes of DEGs were closely associated with nuclear activities, especially cell division. Cell division as a functional category includes mechanisms to properly orient and position the mitotic spindle, which is important because incorrect activity related to the spindle contributes to disease, even carcinogenesis \[[@b23-medscimonit-26-e923934],[@b24-medscimonit-26-e923934]\]. Echoing the KEGG pathway enrichment analysis, the DEGs were strongly related to the cell cycle. Dysregulation of the cell cycle leading to endless proliferation of cells has been implicated in tumorigenesis \[[@b25-medscimonit-26-e923934]\]. Jing Wen et al. \[[@b26-medscimonit-26-e923934]\] found that, *in vitro* and *in vivo*, transcriptional activation of miR-424 elevated proliferation of ESCC cell lines and led to poor survival in ESCC patients; this activation facilitates both G1/S and G2/M cell cycle transitions. However, inhibition of cell cycle progression alleviates the development of malignancy. Chinese researchers have demonstrated that a novel Notch inhibitor called FLI-06 exerts antitumor activity in a dose-dependent manner via cell-cycle arrest and proliferation suppression in ESCC cells \[[@b27-medscimonit-26-e923934]\]. Above all, therapeutic interventions targeting cell division may generate antitumor activity.

Additionally, the KEGG pathway enrichment analysis showed that the DEGs were enriched in the PI3K-Akt signaling pathway, the cGMP-PKG signaling pathway, cytokine-cytokine receptor interaction, and vascular smooth muscle contraction. Intriguingly, those findings differed from those of a similar study using bioinformatics methods conducted by He et al. \[[@b25-medscimonit-26-e923934]\]. Their findings indicated that DEGs related to ECA were mainly enriched in complement and coagulation cascades, mature- onset diabetes in the young, and retinol metabolism. Given that their sample was extracted from ECA patients and ours from patients diagnosed with ESCC and SCEC, it was inevitable for the two studies to find differences. Still, the evidence supporting our scientific results are as follows:

The PI3K-Akt signaling pathway is implicated in several cancers, including breast cancer, colorectal carcinoma, hepatocellular cancer, and others \[[@b28-medscimonit-26-e923934]--[@b30-medscimonit-26-e923934]\]. Invariably, this pathway plays an important role in metastasis and prognosis among ESCA patients \[[@b31-medscimonit-26-e923934],[@b32-medscimonit-26-e923934]\]. Ni Shi et al. \[[@b33-medscimonit-26-e923934]\] showed that MK2206/BEZ235 enhances apoptosis and inhibits tumor growth targeted at AKT phosphorylation in a mouse xenograft model of ESCC and *in vitro*. Moreover, the combination of MK2206 and BEZ235 boost antitumor effects because of dual PI3K and AKT inhibition. Another study demonstrated that Osthole, extracted from the herb *Cnidium monnieri* (L.) Cuss, reduced expression of PI3K and phosphorylated AKT (p-AKT), and thereby decreased ESCC proliferation \[[@b34-medscimonit-26-e923934]\]. Hence, treatments targeting the PI3K-Akt signaling pathway provide a promising approach to prevent ESCA and/or to slow its progression. The cGMP-PKG signaling pathway modulates massive physiological and pathological parameters \[[@b35-medscimonit-26-e923934]\]. Correlation between inflammation and the cGMP-PKG signaling pathway has been identified, involving mechanisms of neutrophil migration, mitochondrial permeability transition, and oscillations of calcium ions \[[@b36-medscimonit-26-e923934],[@b37-medscimonit-26-e923934]\]. Interestingly, the mechanism responsible for dysplasia-induced (especially by Barrett's esophagus) early EAC included a substantial promotion in the levels of inflammatory cytokines \[[@b38-medscimonit-26-e923934]\]. This implies that the cGMP-PKG signaling pathway is possibly connected with ESCA pathology in the early stages. Although studies testing the potential role of pharmacological modulation of the cGMP-PKG signaling pathway as an anticancer therapy are scant, we still hold a positive belief in their potential.

Tumor events are elicited by the collective expression of multiple genes, while single genes function as carcinogens particularly associated with severity \[[@b39-medscimonit-26-e923934]\]. As revealed in the PPI network, coordinated DEGs mediated the occurrence and development of ESCA. To select the critical genes for the interlaced construction, we input information for all DEGs to Cytoscape to screen the top 10 nodes in terms of degree. As a consequence, the degree of TOP2A ranked the highest, followed by UBE2C, BUB1, KIF20A, TTK, CCNB2, KIF2C, TPX2, CCNA2, and CCNB1. These nodes were regarded as hub genes for ESCA. In contrast, He et al. \[[@b25-medscimonit-26-e923934]\] identified IL8, IVL, TIMP1, FN1, SERPINE1, SERPINA1, CFTR, SPP1, COL1A1, and AGT as hub genes for ESCA. They focused on EAC while we focused on ESCC and SCEC. It has been established that there are substantial differences between EAC and ESCC, especially in terms of pathology \[[@b3-medscimonit-26-e923934]\], so it is not surprising to obtain distinct results. Taken together, all 10 hub genes we identified were linked to cell proliferation, involving the cell cycle or chromosome activity. Details about key hub genes are demonstrated as follows:

CCNA2 controls both the G1/S and the G2/M transition phases of the cell cycle, via the formation of specific serine/threonine protein kinase holoenzyme complexes with the cyclin-dependent protein kinases CDK1 or CDK2 \[[@b40-medscimonit-26-e923934]\]. Emerging evidence indicates that miR-219-5p mitigates ESCC cell proliferation by decreasing expression levels of CCNA2. Knockdown of CCNA2 enhances the impacts of miR-219-5p in terms of cell proliferation and cell cycle process \[[@b41-medscimonit-26-e923934]\]. CCNB2 and CCNB1 are elementary parts of the G2/M (mitosis) transition. One of the reasons why the overexpression of erythrocyte membrane protein band 4.1 like 3 (EPB41L3) noticeably improved overall survival rates among ESCA patients was its activation of CCNB1 signaling to induce G2/M cell cycle arrest \[[@b42-medscimonit-26-e923934]\]. A number of studies have found the high expression of CCNB2 to be related to tumor growth and poor prognosis in several cancers, including non-small cell lung carcinomas (NSCLC), hepatocellular carcinoma, and gastric cancer \[[@b43-medscimonit-26-e923934]--[@b45-medscimonit-26-e923934]\]. Without laboratory data on ESCA, the role of CCNB2 is still controversial. Given that CCNB2, CCNA2, and CCNB1 are essential for cell cycle regulation, and are subsidiary to the cyclin family, they have potential as therapeutic targets for ESCA.

KIF20A and KIF2C are implicated in chromosome activity. They belong to the kinesin superfamily, and probably possess the potential to ameliorate malignancy. The kinesin family plays a significant role in microtubule motor activity of several cellular and extracellular structures, including Golgi membranes, chromosomes, associated vesicles along microtubules, and the central spindle \[[@b46-medscimonit-26-e923934]\]. KIF20A is a member of the kinesin-6 subfamily, and is crucial for cytokinesis and spindle assembly. Its expression pattern is linked to tumor development and prognosis \[[@b47-medscimonit-26-e923934]\]. KIF2C is responsible for the majority of microtubule plus-end depolymerizing activity in mitotic cells. It is required for chromosome segregation and congression during mitosis, and regulates the turnover and conversion of microtubules \[[@b48-medscimonit-26-e923934]\]. An immunohistochemical analysis conducted in ESCA tissue and adjacent non-cancerous tissues revealed that higher KIF2C expression led to higher pathologic tumor status and poorer tumor differentiation, but only for male patients \[[@b49-medscimonit-26-e923934]\].

TOP2A controls topological states of DNA, a crucial role for proper segregation of daughter chromosomes during mitosis and meiosis \[[@b50-medscimonit-26-e923934]\]. One clinical study suggested that high TOP2A could serve as a biomarker driving medical therapy \[[@b51-medscimonit-26-e923934]\]. Another study showed that the knockdown of the long noncoding RNA (lncRNA) DDX11-AS1 reversed paclitaxel (PTX) resistance by means of inhibiting the expression level of TOP2A \[[@b52-medscimonit-26-e923934]\]. Both of these results imply that targeting the expression of TOP2A may have promise as a pharmacological treatment.

BUB1 is identified as a mitotic checkpoint that is important for spindle-assembly checkpoint signaling and correct chromosome alignment \[[@b53-medscimonit-26-e923934]\]. The transcriptional level of BUB1 in Barrett's patients, leading to early chromosomal instability (CI), can be helpful in EAC \[[@b54-medscimonit-26-e923934]\]. For the time being, we can hypothesize that treatment modifying BUB1 expression may benefit ESCA patients.

Meanwhile, the expression of UBE2C, TTK, and TPX2 is involved in ESCA pathology and prognosis. As a ubiquitin-conjugating enzyme, UBE2C promotes the degradation of several cell cycle-regulated proteins that control progression through mitosis \[[@b55-medscimonit-26-e923934]\]. Knockdown of UBE2C significantly inhibits cell proliferation via cell-cycle regulation, in *in-vitro* ESCA cell models, particularly in TE-1 cell lines \[[@b56-medscimonit-26-e923934]\]. TTK is associated with cell proliferation and chromosome alignment \[[@b57-medscimonit-26-e923934]\]. Previous clinical trials found that immunotherapies using epitope peptides derived from TTK potentiated cell response and immunity against ESCA \[[@b58-medscimonit-26-e923934],[@b59-medscimonit-26-e923934]\]. TPX2 is required for normal assembly of microtubules as well as mitotic spindles during apoptosis. As detected by RT-qPCR, the relative expression of TPX2 is upregulated in ESCA tumor tissue, and in lymph node metastasis \[[@b60-medscimonit-26-e923934]\]. Moreover, low expression of miR-491 aimed at TPX2 promotes cell invasion in ESCA clinical samples, affecting carcinogenesis and cancer development \[[@b61-medscimonit-26-e923934]\].

Collectively, we identified 210 DEGs and implemented GO analysis, KEGG pathway enrichment analysis, and PPI network construction to understand their possible roles in ESCA carcinogenesis. The enriched KEGG pathway implicated pathological mechanisms in ESCA, including the cell cycle and the PI3K-Akt and cGMP-PKG signaling pathways. Furthermore, we identified 10 hub genes and assessed their prognostic value. The 10 hub genes were TOP2A (highest ranking in terms of degree), UBE2C, BUB1, KIF20A, TTK, CCNB2, KIF2C, TPX2, CCNA2, and CCNB1. These genes showed marked connections with late survival of ESCA patients, indicating their value in diagnosis and survival improvement.

Our research provides new insights for ESCA early diagnosis and survival evaluation, at the level of genes, pathways, and molecular functions. Even though we analyzed two microarray datasets containing data from patients diagnosed with ESCA, the chosen samples in our research are still inadequate for definitive conclusions, especially in light of the scarcity of experimental evidence related to our findings. It will be necessary to validate our research findings through practical experiments, such as immunohistochemistry on tumor tissue and paired healthy control tissue.

Conclusion
==========

In this research, a total of 210 ESCA-related DEGs were found, and their enriched functions and pathways were analyzed using bioinformatics methods. Taking the mechanistic link between enriched pathways and ESCA into consideration, our results may provide helpful information for understanding ESCA pathology and ESCA treatment. The PPI network we constructed from the DEGs revealed that these genes mediate the occurrence and development of ESCA through multi-gene interactions. From these, we selected the top 10 hub genes: TOP2A (highest ranking of degree), UBE2C, BUB1, KIF20A, TTK, CCNB2, KIF2C, TPX2, CCNA2, and CCNB1. These genes are closely associated with the etiology and prognosis of ESCA, and have potential as therapeutic or early-diagnostic biomarkers. Nevertheless, there are some limitations in our research. The absence of laboratory evidence imposes restrictions on the conclusions that can be drawn from our results. In addition, there were no more than 10 ESCA patients in each sample; this sample size may be insufficient. Therefore, in order to verify our findings, further experimental research, such as immunohistochemistry studies and large clinical studies, is needed.
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![Venn diagram of filtered differentially expressed genes (DEGs) shared by the GSE111044 and GSE100942 datasets. The overlapping area, which contained 210 items, was considered to contain DEGs for ESCA.](medscimonit-26-e923934-g001){#f1-medscimonit-26-e923934}

![Top 16 enriched molecular function GO terms. The horizontal axis is a logarithmic calculation of p value, while GO terms are listed on the y axis. The length of each bar represents lower p value (higher significance). Actin binding was the term with the highest significance level.](medscimonit-26-e923934-g002){#f2-medscimonit-26-e923934}

![Top 16 enriched cellular component GO terms. The horizontal axis is a logarithmic calculation of p value, while GO terms are listed on the y axis. The length of each bar represents lower p value (higher significance). Chromosome and centromeric region was the term with the highest significance level.](medscimonit-26-e923934-g003){#f3-medscimonit-26-e923934}

![Top 20 enriched biological process GO terms. The horizontal axis is a logarithmic calculation of p value, while GO terms are listed on the y axis. The length of each bar represents lower p value (higher significance). Cell division was the term with the highest significance level.](medscimonit-26-e923934-g004){#f4-medscimonit-26-e923934}

![Top 20 results from GO functional enrichment analysis. The size of the filled circles indicates statistical significance. Larger circle size indicates lower p value. Circle color indicates type of GO term, as listed in the legend (lower left corner).](medscimonit-26-e923934-g005){#f5-medscimonit-26-e923934}

![The top 20 KEGG pathways involving the differentially expressed genes (DEGs). Rich factor is represented on the x axis. KEGG pathway annotation is represented on the y axis. The size of the filled circles symbolizes the number of genes involved in the pathways. The color of the filled circles denotes significance, with gradation from red to blue symbolizing increasing p value.](medscimonit-26-e923934-g006){#f6-medscimonit-26-e923934}

![PPI network of ESCA-related differentially expressed genes (DEGs). The number of nodes was 202 (with 8 untouched genes). The number of edges was 1571; much higher than the expected 298 edges. The average node degree was 15.6. The average local clustering coefficient was 0.582. The PPI enrichment p value was less than 1.0e-16.](medscimonit-26-e923934-g007){#f7-medscimonit-26-e923934}

![Topological diagram of the top 10 hub genes. In accordance with degree ranking, the top 10 differentially expressed genes (DEGs) were accepted as hub genes. Among all the DEGs, TOP2A was in the highest degree rank, followed by UBE2C, BUB1, KIF20A, TTK, CCNB2, KIF2C, TPX2, CCNA2, and CCNB1.](medscimonit-26-e923934-g008){#f8-medscimonit-26-e923934}

![Differences in expression level of the top 10 hub genes between ESCA tissue and matched normal tissue. The plots are based on TCGA and GTEx data, and reveal that these hub genes are significantly upregulated in ESCA tissue compared with normal tissue (p\<0.01). The red \* denotes statistically significant difference.](medscimonit-26-e923934-g009){#f9-medscimonit-26-e923934}

![GEPIA stage-plots for the top 10 hub genes in patients at different stages of ESCA. The stage-plot is considered statistically significant when Pr \>F. Greater F values represent increasing significance.](medscimonit-26-e923934-g010){#f10-medscimonit-26-e923934}

![Effects of the top 10 hub genes on prognosis of ESCA patients, as calculated by OncoLnc. All of the hub genes improved late survival time of ESCA patients (x\>2000), while few exhibited any association with early survival time.](medscimonit-26-e923934-g011){#f11-medscimonit-26-e923934}

###### 

Details of DEGs filtered from GSE111044 and GSE100942.

  Source                                    Total   Elements
  ----------------------------------------- ------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Intersection of GSE111044 and GSE100942   210     SLMAP, SAMD4A, KCNMA1, LDB3, LINC01279, TPX2, EPB41L4B, WISP2, IGF2BP3, CCNB1, MSRB3, ANP32E, NFIA, CNN1, COL1A1, ANLN, BIRC5, GHR, BCHE, DNMT3B, SMAD9, LRRK2, HLF, ADAMTS2, AURKA, KIF14, FHL1, SORBS2, ADRB1, CSRP1, TCF21, KIF4A, KIT, RAD54B, C1QTNF7, NEGR1, FAM72A, KCNAB1, MELK, CDH11, NDC80, CCNA2, GTSE1, NUF2, KRT78, PDK4, MMP1, MYOCD, EPCAM, ANGPTL1, DAAM2, P2RY14, ECT2, KIF23, DEPDC1, EMCN, LPAR3, OGN, POSTN, NBEA, MYLK, CYSLTR1, CCNB2, PRC1, IGFBP6, TNXB, CEP55, MYOC, CCNE2, MCM2, MCM4, CGNL1, ADIRF, HEY1, SRPX, IL1RN, DLGAP5, RAD51AP1, SMTN, TMEM108, SCN7A, CCDC69, CDCA2, MYL9, LRRN4CL, RHPN2, CDH19, PGM5, SOBP, C2orf40, AOX1, COL1A2, LAPTM4B, GULP1, CFD, RNASE4, NEK2, ABLIM1, KIF26B, LPP, FGL2, CHRDL1, HSPB8, RAP1A, DEPDC1B, CILP, ITIH5, HMGB3, TMEM110, NETO2, SYNPO2, SOX4, PLN, MRVI1, EZH2, TNFSF10, CD36, CAPN14, CFH, MYOT, MT1M, RASEF, EMP1, PGM5-AS1, FAM149A, STEAP4, AOC3, LMOD1, ASPA, TMEM35A, CCL14, MYH11, KIF2C, EBF1, EREG, AGTR1, CDCA7, TNS1, CDC20, RBPMS2, C7, BUB1, CCL2, PRR11, IL6, CPED1, RGS2, COL3A1, DPT, SCARA5, PTPRN2, ATP1A2, CDCA3, IFI6, ATAD2, KNL1, EXOSC7, ADAMTS1, ANOS1, SORBS1, FGF7, STIL, UBE2C, STXBP6, MTURN, CCDC80, CLU, CXCL12, IL36A, SLC35F6, TOP2A, AVPR1A, COL14A1, HELLS, FANCI, IRX2, NEXN, SPC25, KIF18A, BUB1B, DKK1, HJURP, AQP1, LMO3, SOCS2, DTL, ACTG2, ADH1B, MEST, ARHGAP6, HMMR, CAB39L, FAM107A, GPX3, KIF20A, SHISA2, ENC1, PTGS1, CASQ2, CTHRC1, UHRF1, SGO2, MAMDC2, TTK, CDKN3, NCAPG, FXYD3, CENPF, NUSAP1, CRCT1

###### 

GO enrichment analysis of ESCA-related DEGs.

  Category      Term                                                                                                Annotation                    Count      P Value    FDR
  ------------- --------------------------------------------------------------------------------------------------- ----------------------------- ---------- ---------- ----------
  MF            GO: 0042393                                                                                         Histone binding               5          0.040956   43.57063
  GO: 0004672   Protein kinase activity                                                                             9                             0.037858   41.02474   
  GO: 0017048   Rho GTPase binding                                                                                  3                             0.035287   38.83208   
  GO: 0008083   Growth factor activity                                                                              6                             0.029217   33.3507    
  GO: 0003678   DNA helicase activity                                                                               3                             0.026484   30.73641   
  GO: 0042826   Histone deacetylase binding                                                                         5                             0.023265   27.53669   
  GO: 0019901   Protein kinase binding                                                                              10                            0.019069   23.15887   
  GO: 0016887   ATPase activity                                                                                     7                             0.013453   16.91675   
  GO: 0048407   Platelet-derived growth factor binding                                                              3                             0.005775   7.618473   
  GO: 0005201   Extracellular matrix structural constituent                                                         5                             0.005574   7.362384   
  GO: 0005524   ATP binding                                                                                         28                            0.004315   5.745381   
  GO: 0008574   ATP-dependent microtubule motor activity, plus-end-directed                                         4                             7.15E-04   0.97331    
  GO: 0008017   Microtubule binding                                                                                 10                            3.85E-04   0.525754   
  GO: 0008201   Heparin binding                                                                                     9                             3.10E-04   0.423032   
  GO: 0003777   Microtubule motor activity                                                                          7                             2.05E-04   0.280292   
  GO: 0005515   Protein binding                                                                                     118                           1.98E-04   0.271172   
  GO: 0008307   Structural constituent of muscle                                                                    6                             7.85E-05   0.107306   
  GO: 0003779   Actin binding                                                                                       15                            1.63E-06   0.002223   
  CC            GO: 0005814                                                                                         Centriole                     5          0.034311   36.49999
  GO: 0097149   Centralspindlin complex                                                                             2                             0.032082   34.56688   
  GO: 0005694   Chromosome                                                                                          5                             0.0272     30.14128   
  GO: 0070062   Extracellular exosome                                                                               42                            0.0257     28.72761   
  GO: 0005680   Anaphase-promoting complex                                                                          3                             0.025342   28.38631   
  GO: 0005584   Collagen type i trimer                                                                              2                             0.021504   24.62943   
  GO: 0016363   Nuclear matrix                                                                                      5                             0.021056   24.17972   
  GO: 0051233   Spindle midzone                                                                                     3                             0.017618   20.64245   
  GO: 0005925   Focal adhesion                                                                                      11                            0.010247   12.53825   
  GO: 0015629   Actin cytoskeleton                                                                                  8                             0.009682   11.8868    
  GO: 0005654   Nucleoplasm                                                                                         44                            0.008794   10.8543    
  GO: 0005576   Extracellular region                                                                                29                            0.008174   10.12583   
  GO: 0048471   Perinuclear region of cytoplasm                                                                     15                            0.007728   9.598831   
  GO: 0005813   Centrosome                                                                                          12                            0.006822   8.519486   
  GO: 0000922   Spindle pole                                                                                        6                             0.006621   8.277421   
  GO: 0015630   Microtubule cytoskeleton                                                                            7                             0.003771   4.795012   
  GO: 0001725   Stress fiber                                                                                        5                             0.002747   3.514485   
  GO: 0045120   Pronucleus                                                                                          3                             0.002356   3.021411   
  GO: 0005737   Cytoplasm                                                                                           77                            0.001617   2.083603   
  GO: 0005829   Cytosol                                                                                             54                            0.00154    1.984823   
  GO: 0031012   Extracellular matrix                                                                                11                            0.001477   1.904168   
  GO: 0005876   Spindle microtubule                                                                                 5                             0.001282   1.655013   
  GO: 0031262   Ndc80 complex                                                                                       3                             6.88E-04   0.890813   
  GO: 0000942   Condensed nuclear chromosome Outer kinetochore                                                      3                             6.88E-04   0.890813   
  GO: 0005874   Microtubule                                                                                         12                            5.90E-04   0.765086   
  GO: 0030018   Z disc                                                                                              8                             2.97E-04   0.385939   
  GO: 0005581   Collagen trimer                                                                                     8                             6.25E-05   0.081295   
  GO: 0000776   Kinetochore                                                                                         8                             2.74E-05   0.035668   
  GO: 0005871   Kinesin complex                                                                                     7                             2.22E-05   0.028929   
  GO: 0005615   Extracellular space                                                                                 33                            2.02E-05   0.026247   
  GO: 0005578   Proteinaceous extracellular matrix                                                                  14                            7.32E-06   0.009524   
  GO: 0005819   Spindle                                                                                             10                            6.68E-06   0.008694   
  GO: 0000775   Chromosome, centromeric region                                                                      8                             2.59E-06   0.003375   
  GO: 0030496   Midbody                                                                                             11                            1.40E-06   0.001819   
  GO: 0000777   Condensed chromosome kinetochore                                                                    11                            3.37E-08   4.38E-05   
  BP            GO: 0007015                                                                                         Actin filament organization   4          0.048188   55.68998
  GO: 0051436   Negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle             4                             0.046554   54.41983   
  GO: 0001666   Response to hypoxia                                                                                 6                             0.046026   54.00186   
  GO: 0046777   Protein autophosphorylation                                                                         6                             0.046026   54.00186   
  GO: 0044344   Cellular response to fibroblast growth factor stimulus                                              3                             0.045033   53.20648   
  GO: 2000660   Negative regulation of interleukin-1-mediated signaling pathway                                     2                             0.044501   52.77484   
  GO: 0010574   Regulation of vascular endothelial growth factor production                                         2                             0.044501   52.77484   
  GO: 0043154   Negative regulation of cysteine-type endopeptidase activity involved in apoptotic process           4                             0.043372   51.8463    
  GO: 0097421   Liver regeneration                                                                                  3                             0.042339   50.98273   
  GO: 0051384   Response to glucocorticoid                                                                          4                             0.037348   46.59797   
  GO: 0060326   Cell chemotaxis                                                                                     4                             0.037348   46.59797   
  GO: 0007049   Cell cycle                                                                                          7                             0.037147   46.41426   
  GO: 0045840   Positive regulation of mitotic nuclear division                                                     3                             0.034645   44.07219   
  GO: 0071173   Spindle assembly checkpoint                                                                         2                             0.033564   43.03115   
  GO: 0060414   Aorta smooth muscle tissue morphogenesis                                                            2                             0.033564   43.03115   
  GO: 0006977   DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest       4                             0.033134   42.61195   
  GO: 0000070   Mitotic sister chromatid segregation                                                                3                             0.032215   41.70664   
  GO: 0006306   DNA methylation                                                                                     3                             0.032215   41.70664   
  GO: 0042787   Protein ubiquitination involved in ubiquitin-dependent protein catabolic process                    6                             0.030104   39.57493   
  GO: 0051966   Regulation of synaptic transmission, glutamatergic                                                  3                             0.02757    36.92013   
  GO: 0051439   Regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle                      3                             0.02757    36.92013   
  GO: 0043547   Positive regulation of GTPase activity                                                              13                            0.027349   36.68291   
  GO: 0070301   Cellular response to hydrogen peroxide                                                              4                             0.026698   35.9813    
  GO: 1903779   Regulation of cardiac conduction                                                                    4                             0.0255     34.66984   
  GO: 0008283   Cell proliferation                                                                                  10                            0.023601   32.53933   
  GO: 0048146   Positive regulation of fibroblast proliferation                                                     4                             0.023193   32.07322   
  GO: 0000022   Mitotic spindle elongation                                                                          2                             0.022502   31.27789   
  GO: 0001501   Skeletal system development                                                                         6                             0.019827   28.11186   
  GO: 0010881   Regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ions   3                             0.019192   27.33961   
  GO: 0006939   Smooth muscle contraction                                                                           3                             0.017299   24.99359   
  GO: 0051726   Cell cycle regulation                                                                               6                             0.013422   19.96503   
  GO: 0031145   Anaphase-promoting complex-dependent catabolic process                                              5                             0.012345   18.5125    
  GO: 0006957   Complement activation, alternative pathway                                                          3                             0.009152   14.06012   
  GO: 0051310   Metaphase plate congression                                                                         3                             0.007801   12.10953   
  GO: 0055119   Relaxation of cardiac muscle                                                                        3                             0.007801   12.10953   
  GO: 0048565   Digestive tract development                                                                         4                             0.007152   11.1566    
  GO: 0008284   Positive regulation of cell proliferation                                                           13                            0.006888   10.76681   
  GO: 0030574   Collagen catabolic process                                                                          5                             0.005947   9.363414   
  GO: 0034501   Protein localization to kinetochore                                                                 3                             0.005399   8.535467   
  GO: 0032060   Bleb assembly                                                                                       3                             0.005399   8.535467   
  GO: 0007019   Microtubule depolymerization                                                                        3                             0.005399   8.535467   
  GO: 0006268   DNA unwinding involved in DNA replication                                                           3                             0.005399   8.535467   
  GO: 0009612   Response to mechanical stimulus                                                                     5                             0.00445    7.087078   
  GO: 0071549   Cellular response to dexamethasone stimulus                                                         4                             0.004196   6.694943   
  GO: 0019221   Cytokine-mediated signaling pathway                                                                 7                             0.003769   6.034147   
  GO: 0032355   Response to estradiol                                                                               6                             0.00373    5.973802   
  GO: 0001558   Regulation of cell growth                                                                           6                             0.00213    3.453634   
  GO: 0000910   Cytokinesis                                                                                         5                             0.002095   3.397158   
  GO: 0007094   Mitotic spindle assembly checkpoint                                                                 4                             0.00141    2.299434   
  GO: 0000086   G2/M transition of mitotic cell cycle                                                               8                             9.49E-04   1.552707   
  GO: 0007080   Mitotic metaphase plate congression                                                                 5                             7.83E-04   1.283031   
  GO: 0007155   Cell adhesion                                                                                       15                            7.52E-04   1.232171   
  GO: 0007018   Microtubule-based movement                                                                          7                             3.11E-04   0.511889   
  GO: 0030199   Collagen fibril organization                                                                        6                             7.41E-05   0.122099   
  GO: 0006936   Muscle contraction                                                                                  9                             2.91E-05   0.047888   
  GO: 0007052   Mitotic spindle organization                                                                        6                             1.99E-05   0.032833   
  GO: 0000281   Mitotic cytokinesis                                                                                 6                             1.68E-05   0.027614   
  GO: 0007059   Chromosome segregation                                                                              8                             1.15E-05   0.018962   
  GO: 0007062   Sister chromatid cohesion                                                                           12                            2.35E-08   3.87E-05   
  GO: 0007067   Mitotic nuclear division                                                                            20                            5.66E-11   9.33E-08   
  GO: 0051301   Cell division                                                                                       25                            1.55E-12   2.55E-09   

###### 

KEGG pathway enrichment analysis of ESCA-related DEGs.

  Term                                                            Number   Corrected p value   Genes
  --------------------------------------------------------------- -------- ------------------- ---------------------------------------------------------------------
  Cell cycle                                                      10       1.19E-08            CCNB2, CCNB1, CCNA2, BUB1B, CCNE2, CDC20, TTK, MCM4, MCM2, BUB1
  cGMP-PKG signaling pathway                                      9        1.51E-06            MRVI1, MYLK, KCNMA1, ADRB1, ATP1A2, RGS2, PLN, AGTR1, MYL9
  Vascular smooth muscle contraction                              8        2.68E-06            MYH11, MRVI1, AVPR1A, ACTG2, MYLK, KCNMA1, AGTR1, MYL9
  AGE-RAGE signaling pathway in diabetic complications            6        0.000105714         CCL2, IL6, COL1A2, COL1A1, COL3A1, AGTR1
  Pathways in cancer                                              11       0.00016471          CXCL12, CCNE2, BIRC5, KIT, IL6, HLF, FGF7, LPAR3, AGTR1, HEY1, MMP1
  PI3K-Akt signaling pathway                                      9        0.000181898         GHR, CCNE2, KIT, IL6, COL1A2, EREG, COL1A1, FGF7, LPAR3
  Platelet activation                                             6        0.000181898         PTGS1, MYLK, RAP1A, COL1A2, COL1A1, COL3A1
  Calcium signaling pathway                                       7        0.000181898         AVPR1A, CASQ2, MYLK, ADRB1, PLN, AGTR1, CYSLTR1
  Oocyte meiosis                                                  6        0.000181898         CCNB2, CCNB1, BUB1, CCNE2, CDC20, AURKA
  Cytokine-cytokine receptor interaction                          8        0.000256568         CCL2, IL1RN, TNFSF10, GHR, DTL, IL6, IL36A, CXCL12
  Protein digestion and absorption                                5        0.000372719         COL3A1, COL14A1, COL1A2, ATP1A2, COL1A1
  Rheumatoid arthritis                                            5        0.000372719         IL6, CCL2, CXCL12, DTL, MMP1
  Progesterone-mediated oocyte maturation                         5        0.000505745         CCNB2, CCNB1, CCNA2, AURKA, BUB1
  p53 signaling pathway                                           4        0.001955985         CCNE2, CCNB2, CCNB1, GTSE1
  Human T-cell leukemia virus 1 infection                         6        0.001955985         CCNB2, CCNA2, BUB1B, CCNE2, CDC20, IL6
  Adrenergic signaling in cardiomyocytes                          5        0.002613273         ADRB1, AGTR1, SCN7A, ATP1A2, PLN
  Neuroactive ligand-receptor interaction                         7        0.002678945         AVPR1A, GHR, P2RY14, ADRB1, LPAR3, AGTR1, CYSLTR1
  ECM-receptor interaction                                        4        0.003021888         HMMR, COL1A2, CD36, COL1A1
  Cellular senescence                                             5        0.003023275         IL6, CCNB2, CCNB1, CCNE2, CCNA2
  Jak-STAT signaling pathway                                      5        0.003030745         IL6, AOX1, FHL1, GHR, SOCS2
  Tyrosine metabolism                                             3        0.003030745         AOX1, AOC3, ADH1B
  Amoebiasis                                                      4        0.003552075         IL6, COL3A1, COL1A2, COL1A1
  Viral protein interaction with cytokine and cytokine receptor   4        0.004092655         IL6, CCL2, CXCL12, TNFSF10
  Malaria                                                         3        0.005771037         IL6, CCL2, CD36
  Intestinal immune network for IgA production                    3        0.005771037         IL6, CXCL12, DTL
  Focal adhesion                                                  5        0.005771037         MYL9, COL1A2, MYLK, RAP1A, COL1A1
  cAMP signaling pathway                                          5        0.007342941         ADRB1, MYL9, ATP1A2, RAP1A, PLN
  Regulation of actin cytoskeleton                                5        0.007342941         FGF7, CFD, CXCL12, MYLK, MYL9
  Relaxin signaling pathway                                       4        0.008337936         COL3A1, COL1A1, COL1A2, MMP1
  FoxO signaling pathway                                          4        0.008510363         IL6, CCNB2, CCNB1, TNFSF10
  Renin secretion                                                 3        0.011964411         ADRB1, AGTR1, KCNMA1
  Phospholipase D signaling pathway                               4        0.011964411         LPAR3, AGTR1, AVPR1A, KIT
  PPAR signaling pathway                                          3        0.015020846         SORBS1, CD36, MMP1
  Hepatitis B                                                     4        0.015736213         IL6, CCNE2, BIRC5, CCNA2
  Complement and coagulation cascades                             3        0.015736213         CLU, C7, CFH
  Tight junction                                                  4        0.017269759         MYH11, EPB41L4B, RAP1A, MYL9
  Salivary secretion                                              3        0.021192296         ADRB1, KCNMA1, ATP1A2
  MicroRNAs in cancer                                             5        0.021964309         DNMT3B, CCNE2, EZH2, KIF23, SOX4
  IL-17 signaling pathway                                         3        0.021964309         IL6, CCL2, MMP1
  Hematopoietic cell lineage                                      3        0.023983878         IL6, CD36, KIT
  Pancreatic secretion                                            3        0.024052267         KCNMA1, RAP1A, ATP1A2
  Human papillomavirus infection                                  5        0.029816413         CCNE2, CCNA2, COL1A1, COL1A2, HEY1
  Rap1 signaling pathway                                          4        0.029816413         FGF7, LPAR3, RAP1A, KIT
  Prion diseases                                                  2        0.030030738         IL6, C7
  DNA replication                                                 2        0.03062247          MCM4, MCM2
  Leukocyte transendothelial migration                            3        0.03062247          CXCL12, RAP1A, MYL9
  AMPK signaling pathway                                          3        0.035976653         CAB39L, CCNA2, CD36
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